Atara Biotherapeutics (ATRA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Atara Biotherapeutics (ATRA – Research Report) yesterday and set a price ...

The latest research report published by Vantage Market Research, titled "An Increase in Demand and Opportunities for the ...

TD Cowen analyst Phil Nadeau maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report) yesterday. The company’s shares closed ...

Atara Biotherapeutics Inc (ATRA) has disclosed a new risk, in the Corporate Activity and Growth category. Atara Biotherapeutics Inc faces ...

Atara Biotherapeutics Inc ( ($ATRA) ) has released its Q4 earnings. Here is a breakdown of the information Atara Biotherapeutics Inc presented to ...

WOW! Internet, TV & Phone , a leading broadband provider in the United States, announced today it will host a webcast and conference call on Friday, March 14, 2025 at 8:00 a.m. ET to discuss financial ...

Atara Biotherapeutics said it would lay off half of its workforce in a restructuring that came as the company narrowed its loss and logged higher revenue in the fourth quarter. The immunotherapy ...

THOUSAND OAKS, Calif. (AP) — THOUSAND OAKS, Calif. (AP) — Atara Biotherapeutics Inc. (ATRA) on Friday reported a loss of $12.7 million in its fourth quarter. The Thousand Oaks, California ...

Stagwell Inc. (the "Company") announced today the grant of equity inducement awards. Effective March 7, 2025, the Company granted a total of 69,170 restricted stock units to nine new employees. Each ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...